Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
Goel S, Liu J, Guo H, Barry W, Bell R, Murray B, Lynch J, Bastick P, Chantrill L, Kiely BE, Abdi E, Rutovitz J, Asghari R, Sullivan A, Harrison M, Kohonen-Corish M, Beith J. Goel S, et al. Among authors: asghari r. JACC Heart Fail. 2019 Sep;7(9):795-804. doi: 10.1016/j.jchf.2019.04.014. Epub 2019 Aug 7. JACC Heart Fail. 2019. PMID: 31401102 Free article.
Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial.
Chantrill LA, Nagrial AM, Watson C, Johns AL, Martyn-Smith M, Simpson S, Mead S, Jones MD, Samra JS, Gill AJ, Watson N, Chin VT, Humphris JL, Chou A, Brown B, Morey A, Pajic M, Grimmond SM, Chang DK, Thomas D, Sebastian L, Sjoquist K, Yip S, Pavlakis N, Asghari R, Harvey S, Grimison P, Simes J, Biankin AV; Australian Pancreatic Cancer Genome Initiative (APGI); Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial Management Committee of the Australasian Gastrointestinal Trials Group (AGITG). Chantrill LA, et al. Among authors: asghari r. Clin Cancer Res. 2015 May 1;21(9):2029-37. doi: 10.1158/1078-0432.CCR-15-0426. Clin Cancer Res. 2015. PMID: 25896973 Clinical Trial.
The prognostic and predictive value of serum CA19.9 in pancreatic cancer.
Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, Colvin EK, Nagrial A, Chin VT, Chantrill LA, Samra JS, Gill AJ, Kench JG, Merrett ND, Das A, Musgrove EA, Sutherland RL, Biankin AV; NSW Pancreatic Cancer Network. Humphris JL, et al. Ann Oncol. 2012 Jul;23(7):1713-22. doi: 10.1093/annonc/mdr561. Epub 2012 Jan 11. Ann Oncol. 2012. PMID: 22241899 Free PMC article.
A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial.
Davidson A, Veillard AS, Tognela A, Chan MM, Hughes BG, Boyer M, Briscoe K, Begbie S, Abdi E, Crombie C, Long J, Boyce A, Lewis CR, Varma S, Broad A, Muljadi N, Chinchen S, Espinoza D, Coskinas X, Pavlakis N, Millward M, Stockler MR; Australasian Lung cancer Trials Group (ALTG); Australasian Lung cancer Trials Group ALTG. Davidson A, et al. Ann Oncol. 2015 Nov;26(11):2280-6. doi: 10.1093/annonc/mdv373. Epub 2015 Sep 7. Ann Oncol. 2015. PMID: 26347110 Free article. Clinical Trial.
CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan.
Vennin C, Mélénec P, Rouet R, Nobis M, Cazet AS, Murphy KJ, Herrmann D, Reed DA, Lucas MC, Warren SC, Elgundi Z, Pinese M, Kalna G, Roden D, Samuel M, Zaratzian A, Grey ST, Da Silva A, Leung W; Australian Pancreatic Genome Initiative (APGI); Mathivanan S, Wang Y, Braithwaite AW, Christ D, Benda A, Parkin A, Phillips PA, Whitelock JM, Gill AJ, Sansom OJ, Croucher DR, Parker BL, Pajic M, Morton JP, Cox TR, Timpson P. Vennin C, et al. Nat Commun. 2019 Aug 12;10(1):3637. doi: 10.1038/s41467-019-10968-6. Nat Commun. 2019. PMID: 31406163 Free PMC article.
Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence.
Dreyer SB, Upstill-Goddard R, Legrini A, Biankin AV; Glasgow Precision Oncology Laboratory; Jamieson NB, Chang DK; Australian Pancreatic Genome Initiative; Jamieson NB, Chang DK. Dreyer SB, et al. Gastroenterology. 2022 Jan;162(1):320-324.e4. doi: 10.1053/j.gastro.2021.09.022. Epub 2021 Sep 14. Gastroenterology. 2022. PMID: 34534536 Free PMC article. No abstract available.
ROR1 and ROR2 expression in pancreatic cancer.
Liu D, Sharbeen G, Phillips P; Australian Pancreatic Cancer Genome Initiative; Ford CE. Liu D, et al. BMC Cancer. 2021 Nov 11;21(1):1199. doi: 10.1186/s12885-021-08952-9. BMC Cancer. 2021. PMID: 34763666 Free PMC article.
A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer.
Chitty JL, Yam M, Perryman L, Parker AL, Skhinas JN, Setargew YFI, Mok ETY, Tran E, Grant RD, Latham SL, Pereira BA, Ritchie SC, Murphy KJ, Trpceski M, Findlay AD, Melenec P, Filipe EC, Nadalini A, Velayuthar S, Major G, Wyllie K, Papanicolaou M, Ratnaseelan S, Phillips PA, Sharbeen G, Youkhana J, Russo A, Blackwell A, Hastings JF, Lucas MC, Chambers CR, Reed DA, Stoehr J, Vennin C, Pidsley R, Zaratzian A, Da Silva AM, Tayao M, Charlton B, Herrmann D, Nobis M, Clark SJ, Biankin AV, Johns AL, Croucher DR, Nagrial A, Gill AJ, Grimmond SM; Australian Pancreatic Cancer Genome Initiative (APGI); Australian Pancreatic Cancer Matrix Atlas (APMA); Pajic M, Timpson P, Jarolimek W, Cox TR. Chitty JL, et al. Nat Cancer. 2023 Sep;4(9):1326-1344. doi: 10.1038/s43018-023-00614-y. Epub 2023 Aug 28. Nat Cancer. 2023. PMID: 37640930 Free PMC article.
RON is not a prognostic marker for resectable pancreatic cancer.
Tactacan CM, Chang DK, Cowley MJ, Humphrey ES, Wu J, Gill AJ, Chou A, Nones K, Grimmond SM, Sutherland RL, Biankin AV, Daly RJ; Australian Pancreratic Genome Initiative. Tactacan CM, et al. BMC Cancer. 2012 Sep 7;12:395. doi: 10.1186/1471-2407-12-395. BMC Cancer. 2012. PMID: 22958871 Free PMC article.
67 results